Braeckman RA, Manku MS, Ballantyne CM, Stirtan WG, Soni PN. Effects of AMR101, a pure eicosapentaenoic omega-3 fatty acid, on the fatty acid profile in plasma and red blood cells in statin-treated patients with persistent high triglycerides (results from the ANCHOR study) [abstract]. Circulation. 2012;126:A18549.

Braeckman RA, Stirtan WG, Soni PN. Effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) on pharmacokinetic parameters of rosiglitazone in healthy subjects. Clin Pharmacol Drug Dev. 2014 [Epub ahead of print].
Free:
http://onlinelibrary.wiley.com/doi/10.1002/cpdd.150/pdf

Braeckman R, Bays HE, Ballantyne CM, Stirtan WG, Soni PN. Pharmacokinetic and triglyceride-lowering pharmacodynamic effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) across clinical studies [abstract]. Circulation. 2013;128:A19343.

Bays H, Ballantyne CM, Braeckman RA, Stirtan WG, Soni PN. High-sensitivity C-reactive protein effects of icosapent ethyl (eicosapentaenoic acid ethyl ester) with and without stable statin therapy in hypertriglyceridemic patients with metabolic syndrome [abstract]. Circulation. 2013;128:A19342.

Ballantyne CM, Bays HE, Braeckman RA, Philip S, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA. Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies [abstract]. Circulation. 2014;130:A16803.

Brinton EA, Ballantyne CM, Bays HE, Kastelein JJ, Braeckman RA, Soni PN. Effects of AMR101 on lipid and inflammatory parameters in patients with diabetes mellitus-2 and residual elevated triglycerides (200-500 mg/dL) on statin therapy at LDL-C goal: the ANCHOR study [abstract 629-P]. Diabetes. 2012;61(suppl 1):A159-A160.

Braeckman RA, Stirtan WG, Soni PN. Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatin. Clin Drug Investig. 2015 Jan;35(1):45-51.
http://link.springer.com/article/10.1007/s40261-014-0252-8

Ballantyne CM, Braeckman RA, Bays HE, Kastelein JJ, Otvos JD, Stirtan WG, Doyle RT Jr, Soni PN, Juliano RA. Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR study). J Clin Lipidol. 2014 [Epub ahead of print].
Free:
http://www.lipidjournal.com/article/S1933-2874(14)00408-5/pdf

Mason RP, Jacob RF, Corbalan J, Malinski T. Combination treatment with eicosapentaenoic acid and atorvastatin active metabolite reverses endothelial dysfunction in HUVECs exposed to oxidized LDL [abstract]. Presented at the Deuel Conference on Lipids, March 3-6, 2015, Monterey, California.